Australia markets close in 1 hour 6 minutes

Patrys Limited (PAB.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.00900.0000 (0.00%)
As of 01:30PM AEST. Market open.

Patrys Limited

96-100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9670 3273
https://www.patrys.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. James A. Campbell B.Sc., MBA, Ph.D.MD, CEO & Executive Director513.88kN/AN/A
Mr. Stefan RossCompany Secretary12.67kN/AN/A
Dr. Rebecca TunstallVice President of Corporate DevelopmentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Corporate governance

Patrys Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.